Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972374 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00972374 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 44 participants.
The verdict
NCT00972374, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
Interventions
- DRUG 400 ug Brimonidine Implant
- DRUG 200 ug Brimonidine Implant
- OTHER Sham (no implant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972374
The ClinicalTrials.gov registry entry for NCT00972374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 400 ug Brimonidine Implant is the first listed.
NCT00972374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972374 about?
NCT00972374 is a clinical study titled "Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function". This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
What is the current status of trial NCT00972374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2009-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00972374?
The interventions under investigation include: 400 ug Brimonidine Implant (DRUG), 200 ug Brimonidine Implant (DRUG), Sham (no implant) (OTHER).
Who is sponsoring clinical trial NCT00972374?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.